povorcitinib + ICS-LABA

**povorcitinib + ICS-LABA** is a combination therapy under investigation for **moderate to severe asthma** not adequately controlled by standard treatments. This regimen consists of **povorcitinib**, an oral, selective Janus kinase 1 (JAK1) inhibitor, added to an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) background therapy. ICS-LABA refers to standard-of-care inhaled combination therapy (e.g., fluticasone/salmeterol, budesonide/formoterol), which acts on airway inflammation and bronchoconstriction, while povorcitinib targets inflammatory signaling via JAK1 inhibition. The main aim is to improve pulmonary function and reduce asthma exacerbations in patients with persistent asthma despite ICS-LABA use[1][2][3][4][5][8].